Cosmo Pharmaceuticals N.V. / Key word(s): Study resultsCosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeb.
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory ApprovalCosmo announces FDA grants orphan-drug designation ofrifamycin for treatment of pouchitis 20.10.2022 / 06:00 GMT/BSTDublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orpha.
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousGI Genius™ named to FORTUNE 2022 “Change the World” list 12.10.2022 / 06:00 GMT/BSTDublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a medi.
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement04-Oct-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Phar.
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement26-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical In.